E
Cyclerion Therapeutics, Inc.
CYCN
$2.47
-$0.08-3.14%
E
Sell
1/29/2025Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D- on 1/29/2025 due to a decline in the volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D- on 1/29/2025 due to a decline in the volatility index.
D
Sell
1/13/2025Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D- from E+ on 1/13/2025 due to an increase in the volatility index and total return index.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D- from E+ on 1/13/2025 due to an increase in the volatility index and total return index.
E
Sell
11/29/2024Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 11/29/2024 due to a significant decline in the valuation index, efficiency index and solvency index. Total capital declined 6.66% from $8.78M to $8.2M.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 11/29/2024 due to a significant decline in the valuation index, efficiency index and solvency index. Total capital declined 6.66% from $8.78M to $8.2M.
D
Sell
11/12/2024Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D from D+ on 11/12/2024 due to a decline in the volatility index and efficiency index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D from D+ on 11/12/2024 due to a decline in the volatility index and efficiency index.
D
Sell
9/20/2024Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D+ from D on 9/20/2024 due to an increase in the volatility index and total return index.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D+ from D on 9/20/2024 due to an increase in the volatility index and total return index.
D
Sell
9/5/2024Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D from D+ on 9/5/2024 due to a decline in the volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D from D+ on 9/5/2024 due to a decline in the volatility index.
D
Sell
8/16/2024Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D+ from D on 8/16/2024 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 40.89% from -$1.87M to -$1.11M, EBIT increased 14.46% from -$1.62M to -$1.38M, and earnings per share increased from -$0.6183 to -$0.53.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D+ from D on 8/16/2024 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 40.89% from -$1.87M to -$1.11M, EBIT increased 14.46% from -$1.62M to -$1.38M, and earnings per share increased from -$0.6183 to -$0.53.
D
Sell
6/5/2024Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 6/5/2024 due to a significant increase in the efficiency index and solvency index. Net income increased 8.97% from -$1.69M to -$1.54M, and the quick ratio increased from 3.63 to 3.95.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 6/5/2024 due to a significant increase in the efficiency index and solvency index. Net income increased 8.97% from -$1.69M to -$1.54M, and the quick ratio increased from 3.63 to 3.95.
E
Sell
3/30/2023Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D- on 3/30/2023 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 2.42 to 1.77.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D- on 3/30/2023 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 2.42 to 1.77.
D
Sell
3/14/2023Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 2/8/2023 due to a large decline in the growth index and solvency index. The quick ratio declined from 3.1 to 2.42.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 2/8/2023 due to a large decline in the growth index and solvency index. The quick ratio declined from 3.1 to 2.42.
D
Sell
5/16/2022Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 05/16/2022.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 48.73% from -$8.63M to -$12.84M, earnings per share declined from -$0.2484 to -$0.2989, and the quick ratio declined from 4.88 to 4.36.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 48.73% from -$8.63M to -$12.84M, earnings per share declined from -$0.2484 to -$0.2989, and the quick ratio declined from 4.88 to 4.36.
D
Sell
5/4/2022Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 04/21/2022.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 5.52 to 4.88.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 5.52 to 4.88.
D
Sell
11/11/2021Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index. Earnings per share increased from -$0.4532 to -$0.2608, and EBIT increased 26.22% from -$15.3M to -$11.29M.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index. Earnings per share increased from -$0.4532 to -$0.2608, and EBIT increased 26.22% from -$15.3M to -$11.29M.
D
Sell
11/8/2021Downgrade
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
5/1/2020Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. EBIT increased 14.03% from -$28.02M to -$24.09M, operating cash flow increased 6.93% from -$23.81M to -$22.16M, and total revenue increased 5.94% from $1.4M to $1.48M.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. EBIT increased 14.03% from -$28.02M to -$24.09M, operating cash flow increased 6.93% from -$23.81M to -$22.16M, and total revenue increased 5.94% from $1.4M to $1.48M.
D
Sell
1/2/2020Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D- from E on 1/2/2020 due to an increase in the growth index and valuation index. Earnings per share increased from -$1.1775 to -$0.9957, and EBIT increased 15.24% from -$33.05M to -$28.02M.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to D- from E on 1/2/2020 due to an increase in the growth index and valuation index. Earnings per share increased from -$1.1775 to -$0.9957, and EBIT increased 15.24% from -$33.05M to -$28.02M.
E
Sell
10/1/2019Upgraded
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to E from E- on 10/1/2019 due to a large increase in the growth index, total return index and valuation index. Operating cash flow increased 35.9% from -$34.27M to -$21.97M, earnings per share increased from -$1.3642 to -$1.1775, and EBIT increased 10.13% from -$36.78M to -$33.05M.
Cyclerion Therapeutics, Inc. (CYCN) was upgraded to E from E- on 10/1/2019 due to a large increase in the growth index, total return index and valuation index. Operating cash flow increased 35.9% from -$34.27M to -$21.97M, earnings per share increased from -$1.3642 to -$1.1775, and EBIT increased 10.13% from -$36.78M to -$33.05M.
E
Sell
6/26/2019None
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E- from U on 06/26/2019.
Cyclerion Therapeutics, Inc. (CYCN) was downgraded to E- from U on 06/26/2019.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
